Spyre Therapeutics (SYRE) director McKenna received 8,026 Stock Option (Right to Buy)
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Mark C. McKenna (director at Spyre Therapeutics Inc., SYRE) reported that they received 8,026 Stock Option (Right to Buy) on May 27, 2026.
- Reporting person
- McKenna Mark C.
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| May 27, 2026 | Grant or award (A) | Stock Option (Right to Buy)On 8,026 Common Stock1 | +8,026 | - | - | 8,026 direct |
Holdings before and after
- Stock Option (Right to Buy): 0 to 8,026 direct
Footnotes from the filing
- 1. This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did McKenna report in this SYRE Form 4?
Mark C. McKenna (director at Spyre Therapeutics Inc., SYRE) reported that they received 8,026 Stock Option (Right to Buy) on May 27, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for SYRE
Across the 24 sessions after earlier SYRE headlines, the stock closed higher 19 times and lower 5 times, with a median move of 2.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SYRE | SPY |
|---|---|---|---|
| May 27, 2026 | Spyre Therapeutics to Participate in Upcoming June Investor Conferences | -1.5% | -0.0% |
| May 5, 2026 | Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | +2.7% | +0.8% |
| May 4, 2026 | Spyre Therapeutics Announces Grants of Inducement Awards | -0.4% | -0.4% |
| Apr 17, 2026 | Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million | +4.7% | +1.2% |
| Apr 15, 2026 | Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock | +7.8% | +0.8% |
| Apr 14, 2026 | Raymond James initiated coverage on Spyre Therapeutics with a new price targetand 1 other headline that session | +1.2% | +1.2% |
Earlier insider filings at SYRE
- May 29, 2026SEC Form 4 filed by Director Milligan Sandra
- May 9, 2026Director Henderson Michael Thomas sold $5,952,050 worth of shares (80,000 units at $74.40) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 88,606 units (SEC Form 4)
- May 2, 2026Chief Financial Officer Burrows Scott L exercised 12,500 shares at a strike of $14.50 and sold $892,125 worth of shares (12,500 units at $71.37) as part of a pre-agreed trading plan (SEC Form 4)
- May 2, 2026Chief Medical Officer Sloan Sheldon exercised 78,333 shares at a strike of $27.46 and sold $5,600,701 worth of shares (78,333 units at $71.50) as part of a pre-agreed trading plan (SEC Form 4)
- May 2, 2026Chief Executive Officer Turtle Cameron sold $1,070,507 worth of shares (15,000 units at $71.37) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 612,540 units (SEC Form 4)
Quantisnow market dataNASDAQ
SYRE
Spyre Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2016
Get push alerts for SYRE
Full SYRE profile on Quantisnow Follow SYRE and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time